Outlook Therapeutics, Inc. is a late clinical-stage biopharmaceutical company focused on developing and introducing the first FDA-approved ophthalmic formulation of bevacizumab for retinal indications.
The company's primary areas of focus include wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO).
Generated from their website's infomation